Webcast to be held Monday, September 23, at 8:00 a.m. ET
Sept. 22, 2024 -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to disclose initial phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC on Monday, September 23, 2024, at 8:00am ET.
Black Diamond Therapeutics is a clinical-stage oncology company developi